Health Care & Life Sciences » Biotechnology | VistaGen Therapeutics Inc.

VistaGen Therapeutics Inc.

VistaGen Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.89
Market Cap
$30.01 M
Shares Outstanding
42.62 M
Public Float
39.65 M

Profile

Address
343 Allerton Avenue
South San Francisco California 94080
United States
Employees -
Website http://www.vistagen.com
Updated 07/08/2019
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines for depression and other diseases and disorders of the central nervous system. It focuses on AV-101 product, an oral, non-opioid and non-sedating therapy that offers the potential to be a new at-home treatment for multiple central nervous system indications with high-unmet medical need. The company was founded by H.

Financials

View All

Shawn K. Singh
Chief Executive Officer & Director
H. Ralph Snodgrass
President, Director & Chief Scientific Officer